Drug

SP-26

Ketamine Implant for Fibromyalgia

Drug:

Subcutaneous time-released ketamine-based injectable dissolvable implant.

  • Preclinical research.

Unmet need:

  • Only FDA-approved drugs for fibromyalgia are 2 antidepressants and 1 anti-seizure medicine.

  • Chronic pain treatment market projected growth to $106.3B in 2028 at 7.9% CAGR.

  • Global fibromyalgia treatment market projected growth to $4.1B in 2032 at 4.3% CAGR.

Medical needs:

  • Ketamine-based therapeutic implant targeting fibromyalgia.
  • Self-administered treatment.
  • Safely regulated dosage and time release.
    Previous Drug
    Next Drug

    Competitive advantages:

    • Innovative non-opioid chronic pain therapeutic.
    • Implant method designed to safely regulate dosage and time release.
    • Attractive alternative to intravenous delivery
    Previous Drug
    Next Drug

    Get more information on Silo Pharma. Sign up for email alerts online.

    SIGN UP